Syndax closes on $40m in funding
Syndax, a Waltham biopharmaceutical company, announced today the closing of a $40 million Series A financing.
The firm, which focuses on developing and commercializing novel cancer therapies, said the funds will be used to develop a clinical pipeline.
The financing was co-led by Domain Associates LLC of Princeton, N.J., a venture capital firm with an exclusive focus on life sciences, and MPM Capital, another firm that invests in life sciences; MPM has offices in Boston.
"The financing allows us to execute plans to initiate several clinical trials this year," Syndax chief executive Joanna Horobin said in a statement. "We expect to announce shortly the in-licensing of a lead product candidate, which should move forward rapidly in development."
(By Chris Reidy, Globe staff)
